“Every man is born a twin, the one he is, and the one he believes himself to be.”

– Martin Kessel

Precision medicine has progressively reshaped modern healthcare by challenging the traditional “one-size-fits-all” approach to diagnosis and treatment. Advances in genomics, imaging, and data analytics have expanded the ability to characterize patient heterogeneity, yet the translation of this knowledge into adaptive and anticipatory clinical decision-making remains incomplete. A central limitation lies in the static nature of most clinical models, which struggle to capture the temporal evolution of disease and treatment response. In this context, digital-twin technology has emerged as an evolving paradigm with the potential to bridge this gap, offering a dynamic and integrative framework for precision medical care¹.

Originally conceived in engineering and manufacturing, a digital twin refers to a digital replica of a physical system that is continuously updated through real-time data exchange. In industrial applications, digital twins are used to predict system behavior, optimize performance and anticipate failures^2,3. Translating this concept into medicine presents unique challenges, as biological systems are inherently complex, adaptive, and only partially observable. Nevertheless, the fundamental principle of coupling mechanistic understanding with continuous data assimilation aligns closely with the objectives of personalized and predictive healthcare^4,5.

Crucially, the emergence of digital twins in medicine should not be viewed as a disruptive technological leap, but rather as the culmination of decades of progress in physiological modeling, systems biology, and in silico medicine. Early mathematical models of biological processes – ranging from enzymatic kinetics to organ-level dynamics – provided foundational insights into disease mechanisms. Over time, these models evolved from population-level abstractions to patient-specific representations as clinical data became increasingly accessible. Digital twins represent the logical extension of this trajectory, distinguished not by the novelty of modeling itself, but by the integration of continuous feedback and longitudinal adaptation⁶.

Traditional computational models and simulations have been instrumental in advancing biomedical research and therapeutic development. However, their clinical impact has often been limited by their episodic and offline nature. Simulations are typically performed under fixed assumptions and do not update as new patient data become available. As a result, their relevance to real-time clinical decision-making is constrained. Digital twins aim to overcome these limitations by embedding models within adaptive frameworks that continuously assimilate clinical data, enabling predictions that evolve alongside the patient⁷.

This shift has important implications for how disease is conceptualized and managed. In a digital-twin framework, the model is no longer a static representation of a disease state, but a living computational entity that mirrors disease progression, treatment response, and patient-specific variability over time. By enabling the simulation of alternative clinical scenarios, such as changes in therapy, lifestyle interventions, or disease trajectories, digital twins offer a means to explore the future consequences of medical decisions before they are implemented in practice⁸.

The relevance of this paradigm is particularly evident in chronic and complex conditions, where disease management requires long-term adaptation rather than isolated interventions. Among these, hereditary metabolic diseases represent a compelling, yet underexplored, domain for the application of digital twins. These conditions are often characterized by well-defined biochemical pathways, measurable biomarkers, and lifelong disease trajectories, making them particularly amenable to quantitative modeling and longitudinal monitoring⁹.

Historically, hereditary metabolic disorders have been described using mechanistic models capturing enzymatic deficiencies, altered metabolic fluxes, and the accumulation of toxic metabolites. Classical examples include phenylketonuria, urea cycle disorders, glycogen storage diseases, and other inborn errors of metabolism, where disease mechanisms can be traced to well-characterized biochemical pathways. While such models have been instrumental in elucidating disease pathophysiology and informing therapeutic principles, their clinical applicability has remained constrained by their static formulation and population-based assumptions.

In clinical practice, however, the course of hereditary metabolic diseases is inherently dynamic and highly individualized. Longitudinal variability in biomarkers, such as plasma amino acids, ammonia levels or liver function parameters, interacts with growth, dietary adherence, intercurrent illness, and treatment compliance, producing disease trajectories that differ substantially across patients and across the lifespan. The integration of patient-specific data, including repeated biochemical measurements, anthropometric development, and real-world treatment adherence, creates an opportunity to transform traditional mechanistic models into digital twins capable of evolving alongside the individual patient.

Within this framework, digital twins may support a shift from reactive to proactive metabolic care. Rather than responding to overt metabolic decompensation, digital twins could enable the early identification of destabilizing trajectories, anticipate periods of increased vulnerability, and inform the dynamic optimization of dietary, pharmacological, or supportive interventions. In hereditary metabolic diseases, acute crises can have irreversible consequences. This anticipatory capacity represents not merely an incremental improvement, but a qualitative change in disease management.

Beyond hereditary metabolic disorders, the broader alignment between digital twins and precision medicine is evident across multiple clinical domains. Precision medical care increasingly depends on the integration of heterogeneous data sources, including clinical records, imaging, laboratory measurements and patient-generated data. Digital twins provide a unifying computational framework in which these disparate data streams are contextualized within patient-specific models, enabling predictions that evolve as new information emerges. By embedding temporal adaptation into clinical reasoning, digital twins support a transition from episodic, reactive care toward continuous, forward-looking medical decision-making.

Despite their promise, the translation of Digital Twins into routine clinical practice remains at an early stage and is accompanied by substantial challenges. One of the most pressing issues concerns model validation and trust. In engineering, digital twins can be validated against clearly defined performance metrics. In medicine, validation is complicated by biological variability, incomplete observability, and ethical constraints on experimentation. Robust validation strategies, including prospective clinical studies and uncertainty quantification, are essential to ensure patient safety and clinical acceptance.

Data quality and interoperability pose additional barriers. Digital twins depend on the reliable integration of longitudinal and multimodal data, yet healthcare data remain fragmented across systems and institutions. Without standardized data infrastructures and governance frameworks, the scalability and reproducibility of digital-twin applications will remain limited. Addressing these challenges will require coordinated efforts among healthcare providers, regulators, and technology developers.

Ethical considerations further complicate the deployment of digital twins in medicine, particularly when applied to rare and hereditary diseases. Issues related to data ownership, informed consent, transparency, and algorithmic bias must be carefully addressed. Moreover, as digital twins increasingly incorporate machine learning components, ensuring interpretability and accountability becomes critical to maintaining trust among clinicians and patients alike.

From a clinical perspective, the success of Digital Twins will depend not only on technical performance but also on meaningful integration into clinical workflows. Tools that increase cognitive burden or disrupt established practices are unlikely to achieve widespread adoption. Instead, Digital Twins must be designed to complement clinical expertise, providing decision support that is interpretable, timely, and contextually relevant¹⁰.

Looking ahead, the future of Digital Twins in precision medical care will likely be shaped by incremental progress rather than sweeping transformation. Targeted applications in domains, such as hereditary metabolic diseases, where disease mechanisms are well characterized and clinical needs are substantial, may serve as proving grounds for broader adoption. Emphasizing methodological rigor, transparency, and clinical relevance over technological novelty will be essential to realizing the full potential of this paradigm.

In conclusion, digital-twin technology represents a conceptual evolution in how medical knowledge, data, and decision-making converge. By enabling continuously evolving, patient-specific representations of disease, digital twins offer a promising pathway toward more predictive, adaptive, and personalized medical care. Their successful integration into healthcare systems will depend on sustained interdisciplinary collaboration, rigorous validation, and ethical stewardship, particularly in sensitive areas such as hereditary metabolic diseases.

Conflict of Interest:

The author declares no conflicts of interest.

Ethics Approval and Informed Consent:

Not required due to the nature of the article.

ORCID ID

Andrea Pession: 0000-0002-0379-9562

References

1. Silva A, Vale N. Digital twins in personalized medicine: bridging innovation and clinical reality. J Pers Med 2025; 15: 503.
2. Grieves M. Digital Twin: Manufacturing Excellence through Virtual Factory Replication. White Paper; 2014.
3. Vickers, J. Digital Twin: Origins and future of a disruptive technology. NASA Technical Report; 2016.
4. Hunter P, Nielsen P. A strategy for integrative computational physiology. Physiology (Bethesda) 2005; 20: 316-325.
5. Viceconti M, Henney A, Morley-Fletcher E. In silico clinical trials: how computer simulation will transform the biomedical industry. Int J Clin Trials 2016; 3: 37-46.
6. Björnsson B, Borrebaeck C, Elander N, Gasslander T, Gawel DR, Gustafsson M, Jörnsten R, Lee EJ, Li X, Lilja S, Martínez-Enguita D, Matussek A, Sandström P, Schäfer S, Stenmarker M, Sun XF, Sysoev O, Zhang H, Benson M; Swedish Digital Twin Consortium. Digital twins to personalize medicine. Genome Med 2019; 12: 4.
7. Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. Nat Med 2019; 25: 44-56.
8. Wilkinson MD, Dumontier M, Aalbersberg IJ, Appleton G, Axton M, Baak A, Blomberg N, Boiten JW, da Silva Santos LB, Bourne PE, Bouwman J, Brookes AJ, Clark T, Crosas M, Dillo I, Dumon O, Edmunds S, Evelo CT, Finkers R, Gonzalez-Beltran A, Gray AJ, Groth P, Goble C, Grethe JS, Heringa J, ‘t Hoen PA, Hooft R, Kuhn T, Kok R, Kok J, Lusher SJ, Martone ME, Mons A, Packer AL, Persson B, Rocca-Serra P, Roos M, van Schaik R, Sansone SA, Schultes E, Sengstag T, Slater T, Strawn G, Swertz MA, Thompson M, van der Lei J, van Mulligen E, Velterop J, Waagmeester A, Wittenburg P, Wolstencroft K, Zhao J, Mons B. The FAIR Guiding Principles for scientific data management and stewardship. Sci Data 2016; 3: 160018.
9. Tebani A, Afonso C, Marret S, Bekri S. Omics-based strategies in precision medicine: toward a paradigm shift in inborn errors of metabolism investigations. Int J Mol Sci 2016; 17: 1555.
10. Torresi G, Verna R. Digital twins: A new paradigm for innovation in clinical research and medical affairs. Malays J Pathol 2025; 47: 355-368.